Compounds > captopril
Page last updated: 2024-08-23

captopril and Weight Loss

captopril has been researched along with Weight Loss in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bult, H; Herijgers, P; Mubagwa, K; Nevelsteen, I; Van den Bergh, A; Van der Mieren, G; Vanderper, A1
Beineke, A; Kuttler, B; Lorenz, G; Mullins, JJ; Nicolai, O; Peters, BS; Peters, J; Rettig, R; Thiele, A1
Capelari, DN; Ciuffo, GM; Fuentes, LB; Ortega, HH; Sánchez, SI1
de Resende, MM; Greene, AS; Kriegel, AJ1
Andrés, A; Hernández, E; León, M; Praga, M; Rodicio, JL; Ruilope, LM1

Trials

1 trial(s) available for captopril and Weight Loss

ArticleYear
Effects of body-weight loss and captopril treatment on proteinuria associated with obesity.
    Nephron, 1995, Volume: 70, Issue:1

    Topics: Adult; Aged; Blood Pressure; Captopril; Creatinine; Female; Humans; Male; Middle Aged; Obesity; Prospective Studies; Proteinuria; Treatment Outcome; Weight Loss

1995

Other Studies

4 other study(ies) available for captopril and Weight Loss

ArticleYear
NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss.
    Journal of vascular research, 2013, Volume: 50, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Blood Glucose; Caloric Restriction; Captopril; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Endothelium, Vascular; Female; Hypertension; Leptin; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Nitric Oxide; Receptors, LDL; Time Factors; Vasodilation; Vasodilator Agents; Weight Loss

2013
The renin-angiotensin system as a primary cause of polyarteritis nodosa in rats.
    Journal of cellular and molecular medicine, 2010, Volume: 14, Issue:6A

    Topics: Animals; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Antinuclear; Blood Pressure; Body Weight; Captopril; CD3 Complex; Cell Movement; Cytochrome P-450 CYP1A1; Indoles; Male; Polyarteritis Nodosa; Rats; Rats, Transgenic; Renin; Renin-Angiotensin System; T-Lymphocytes; Weight Loss

2010
Effects of maternal captopril treatment during late pregnancy on neonatal lung development in rats.
    Regulatory peptides, 2012, Aug-20, Volume: 177, Issue:1-3

    Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Biomarkers; Captopril; Cell Differentiation; Cell Proliferation; Female; Lung; Male; Myofibroblasts; Organ Size; Peptidyl-Dipeptidase A; Pregnancy; Prenatal Exposure Delayed Effects; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Weight Loss

2012
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
    Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:6

    Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Congenic; Atrial Natriuretic Factor; Blood Pressure; Captopril; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Injections, Subcutaneous; Myocardium; Organ Size; Random Allocation; Rats; Rats, Inbred Strains; Spironolactone; Ventricular Function, Left; Weight Loss

2006